Patient Square Capital Acquires New Position in Nektar Therapeutics
Patient Square Capital LP disclosed the purchase of 210,000 shares of Nektar Therapeutics (NASDAQ:NKTR) for $11.96 million as part of a new position representing 2.68% of its reportable AUM at quarter-end. The stock has surged over 669% year-to-date and is valued at $70.62 per share, with the company operating in oncology and immunotherapy development.
Tickers: $NKTR